Upcoming Medical Conferences in BostonSearch Criteria : United States of America Boston
Jan 27 - 31, 2020 | CME 36.00 | USD $1795 | Boston, Massachusetts
Updates in General Internal Medicine for Specialists 2020 is organized by Harvard Medical School (HMS) and will be held from Jan 27 - 31, 2020 at Fairmont Copley Plaza, Boston, Massachusetts, United States of America. Who Should Attend: Specialists from all disciplines can rely on this program for updates in general medicine that impact day-to-day practice, clinical decisions, and patient care. • Physicians • Surgeons • Nurse Practitioners • Advanced Practice Nurses • Physician Assistants Credits: • 36.00 AMA PRA Category 1 Credits™ • 36.00 AAFP Prescribed credits • 5 credits of Risk Management Study. Course Description: We understand that as a specialist, you must keep your knowledge of general medicine current, especially with clinical practice in relevant disciplines outside of your field of expertise. Whether you are a psychiatrist or pathologist, cardiologist or rheumatologist, surgeon or hospitalist, you can rely on this course for updates in general medicine that impact day-to-day practice, clinical decisions, and patient care. We have developed the curriculum for General Internal Medicine for Specialists to provide broad and inclusive content from the disciplines that interface with every specialty. Our curriculum includes updates in the most prevalent conditions, reviews exciting new and innovative therapies, and addresses key clinical controversies that will impact your professional work with patients and peers. We provide updates in several areas including: • Current guidelines and management strategies for diabetes, cardiovascular disease, lipid disorders, hypertension, chronic lung disease, sleep disturbances, cognitive decline, and chronic pain • Strategies for assessing and managing interacting comorbidities • Potential adverse interactions between medications you prescribe and those prescribed by others • Focused examination techniques: basic orthopedics and the neurologic examination • Up-to-date interventional therapies in cardiology, rheumatology, gastroenterology, neurology, dermatology and more • Inter-specialty clinical decision-making • New evidence-based screening and prevention practices • Breakthrough innovations with powerful patient benefit Learning Objectives: Upon completion of this activity, participants will be able to: • Design more effective clinical strategies based on a refreshed understanding of the newest and most effective interventions offered by specialty colleagues. • Recognize current disease prevention and screening guidelines. • Anticipate and manage potential adverse effects of therapies prescribed by other specialists. • Innovate your own clinical care based on a broader understanding of the management strategies and clinical decision-making of colleagues, including the rationale for specific modalities and medications. • Employ treatments and interventions provided by primary care internal medicine and specialist physicians. • Develop response strategies for critical medication interactions. • Assess the added value of new diagnostic and screening tests. • Discuss the basis for current treatment guidelines, diagnostic recommendations, and management strategies for diabetes, hypertension, hypercholesterolemia, ischemic heart disease, memory loss, pain, sleep disorders, stroke management, anemia, anticoagulant use and many other specific conditions. • Assess the relative efficacy and cross-specialty implications of innovative biomodulator therapies used in a broad spectrum of specialties. • Develop treatment plans in specific common clinical situations that cut across specialties, such as chronic pain, screening, health promotion. • Recognize the impact of the opioid epidemic and how to participate in national efforts to address this crisis. Topics covered in the 2020 program include: • Ischemic heart disease • Antibiotic use in office practice • Hepatitis • Reducing fractures • Stroke • Chronic obstructive lung disease • Diabetes management • Women’s health • Anticoagulation • Endocrinology • The neurologic exam • Cognitive decline • Travel medicine • Congestive heart failure • Common eye problems • Diseases of the foregut • Preoperative evaluation • Breast cancer • Differential dx of polyarthritis • IBS and IBD • Atrial fibrillation • Lipid management • Dermatology • Osteoporosis management • Asthma • Renal medicine • Anemia • Basic orthopedics • Antiplatelet agents • Sleep disorders • ENT • Managing obesity • Headaches • Allergy medicine • Thyroid disorders • Hypertension • Cancer screening • Non-opioid and opioid pain management • Low back pain
Jan 28 - 30, 2020 | USD $3897 | Boston, Massachusetts
PARP & DDR Inhibitors Summit is organized by Hanson Wade and will be held from Jan 28 - 30, 2020 at Revere Hotel Boston Common, Boston, Massachusetts, United States of America. Description: PARP and novel DNA Damage Response (DDR) inhibitors are showing great potential in broader tumor indications as they advance through the clinic. This industry-focused summit will equip you with the tools to optimize PARP inhibitors for expanded indications; create best-in-class therapeutics; over-ride resistance and identify novel DDR and synthetic lethal pathways to exploit cancer survival mechanisms. • Leverage drug and therapeutic combinations with lessons learnt from PARP in the clinic • Devise personalized treatment plans by examining genotypes and discuss biomarker strategy • Equip your DDR inhibitors for use in expanded indications • Inform therapeutic combination selection to overcome acquired resistance • Analyze the emerging DDR therapeutic landscape and unpick the complex DDR network The PARP & DDR Inhibitors Summit 2020 gathers the VPs, Heads and Directors of Translational Oncology, Target Discovery, and Early Drug Development. This meeting is the perfect opportunity to gain cutting-edge insights from industry leaders on PARP inhibitor development, creating best-in-class therapeutics, over-riding resistance and identifying novel synthetic lethal pathways to exploit cancer survival mechanisms. Step out of the office and into a meeting tailored to your niche. Round table talks, panel discussion and networking provide a unique opportunity for open conversation with industry leaders to accelerate your DDR success. Additional details will be posted as soon as information is available.
Jan 28 - 30, 2020 | Boston, Massachusetts
4th Commercializing Continuous Processing in Pharma (CCP) Summit 2020 is organized by Hanson Wade and will be held from Jan 28 - 30, 2020 at The Colonnade Hotel, Boston, Massachusetts, United States of America. Description: Safety, Efficacy, Efficiency and Quality: Scaling Your Continuous Processing from Technology to Commercial Manufacturing Four years in the drug development world isn’t long, and the progress made in continuous processing has been an extraordinary. Thanks to the encouragement of the FDA and maturing technology; both pharma and biotech are starting to adopt continuous manufacturing (CM) in a commercial setting. Over the last 12 months we have seen major milestones in continuous manufacturing globally – PROSPECT project in the UK, GSK’s announcement of CM facilities in Singapore, Merck has filed an NDA under CM approach, Bill and Melinda Gates Foundation granted $14.3m to Univercells to deploy CM for measles and rubella vaccine continuous manufacturing. At the 4th Annual CCP Summit we will continue to explore scientific and technology advancements that can help eliminate bottlenecks, and more importantly, will address the quality, upfront investment and business rationale behind the ‘switch’. Returning to Boston for the 4th time on Jan 28 - 30, 2020 – Get involved now! Highlights of the 2020 Summit: • FDA reveals their Advanced Manufacturing for Complex Biologics Products program to clarify your myths and help you gain early access to engage with the right teams at the agency • ICH Q13 steering committee members present their latest progresses in draft guidance, and how will this impact your continuous manufacturing in a global framework • Merck shares their implementation of continuous manufacturing for OSD drug products – and how they built the business case early enough to promote timely entry into development cycle • Amgen discusses their virtual plant development, moving towards a truly end-to-end continuous manufacturing process by an integrated systems-based modelling, improving their process robustness and control strategy to drive product quality • Codiak Biosciences, Bristol-Myers Squibb and ImmunoGen showcase their latest technical continuous bioprocessing updates – from upstream to downstream – how CM can provide a more flexible and efficient biomanufacturing Time: 8:00 am to 5:30 pm
Jan 30 - Feb 01, 2020 | USD $280 | Boston, Massachusetts
Yankee Dental Congress (YDC) 2020 is organized by Massachusetts Dental Society (MDS) and will be held from Jan 30 - Feb 01, 2020 at Boston Convention and Exhibition Center, Boston, Massachusetts, United States of America. Description: Yankee Dental Congress is New England’s largest meeting for professionals seeking the highest quality dental continuing education, as well as dental products, services, and resources. With 26,000 dental professionals in attendance encompassing all member of the dental team, Yankee Dental Congress is the fifth largest dental meeting in the country. Held in Boston each January, Yankee is the best source in New England for industry professionals on the cutting-edge of oral health care. Yankee will be “Advancing the Vision” this year with a wide variety of 300+ continuing education courses taught by industry experts, including 125+ free courses. Attendees will be able to gain insight on evolving trends and best practices by visiting over 400 exhibitors demonstrating the most innovative dental technology solutions in the industry. With the largest gathering of dental professionals in the region, Yankee 2020 provides the opportunity to increase your perspective and grow your dental professional network. Additional details will be posted as soon as information is available.
Feb 07 - 09, 2020 | Boston, Massachusetts
School Mental Health: Treating Students K-12 is organized by Harvard Medical School (HMS) and will be held from Feb 07 - 09, 2020 at Fairmont Copley Plaza, Boston, Massachusetts, United States of America. Additional details will be posted as soon as they are available.
Feb 10 - 12, 2020 | USD $295 | Boston, Massachusetts
The 8th Annual Global Pharmaceutical and Medical Meetings Summit is organized by World Congress and will be held from Feb 10 - 12, 2020 at The Westin Boston Waterfront, Boston, Massachusetts, United States of America. Who Should Attend? You will benefit from attending this event if you are a Senior Meetings Professional at a Pharmaceutical, Biotech or Medical Device company, a Contract Research Organization, a Meeting Management company, a Medical Education company or Medical Association, with responsibility in the following areas: • Meeting / Event / Trade Show or Conference Management • Procurement / Purchasing / Strategic Sourcing • Business Travel • Clinical Operations • Program Management • Sales Training • Medical Communications • Professional or Medical Education • Speaker Relations • Marketing • Human Resources Additional details will be posted as soon as information is available.
Neurology Department M&M Conference is organized by Boston University and will be held on Feb 18, 2020 at Boston University School of Medicine, Boston, Massachusetts, United States of America. Target Audience: The target audience for this activity is all neurology faculty and trainees. Accreditation: Boston University School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Objectives: • Identify and present adverse events in an objective, non-judgmental, and educational manner with an aim to identify areas of systemic improvement. • Discuss difficult cases with the same aim of identifying systems errors. • Incorporate the learning points from the discussion to improve their practice in regards to patient safety. Additional details will be posted as soon as information is available.
Feb 24 - 28, 2020 | CME 32.00 | USD $3750 | Boston, Massachusetts
Intensive Course in Transcranial Magnetic Stimulation (TMS) is organized by Berenson-Allen Center for Noninvasive Brain Stimulation (BA CNBS) and will be held from Feb 24 - 28, 2020 at The Berenson-Allen Center for Noninvasive Brain Stimulation, Boston, Massachusetts, United States of America. This Conference has been approved for a maximum of 32 AMA PRA Category 1 Credits™. Description: This intensive transcranial magnetic stimulation (TMS) course provides a unique opportunity for hands-on learning of the basic principles, standards of use, and potential applications of TMS in clinical neurophysiology, cognitive neuroscience, neurology, and psychiatry. It is a one-week course offered three times per year. The course is conducted in small groups of up to 24 participants with formal teaching sessions and ample practical exposure. At the end of the course participants will have learned and directly experienced how to determine motor threshold, how to record motor evoked potentials, how to conduct cortical mapping, silent period, input-output curve, and paired-pulse TMS studies, and how to safely apply repetitive TMS. Participants will have also learned how to design TMS studies, write TMS protocols and interpret findings of TMS studies.This course is limited to 24 participants per session. Note: This course is limited to 24 participants per session. Additional details will be posted as soon as they are available.
Feb 25 - 27, 2020 | USD $2699 | Boston, Massachusetts
3rd Antigen-Specific Immune Tolerance Drug Development Summit is organized by Hanson Wade and will be held from Feb 25 - 27, 2020 at The Colonnade Hotel, Boston, Massachusetts, United States of America. Description: The meeting will bring together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen-specific immunotherapies, ASIT 2020 is the only antigen-specific summit offering thought leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development. Join the 3rd Antigen-Specific Immune Tolerance Summit to: • Hear from and engage with a world-class speaking faculty made up of 26 industry representatives including Novo Nordisk, Pfizer, Merck, Eli Lilly, ITN & FDA • Explore cross learning opportunities from parallel fields tackling immune tolerance and better understand the fundamental mechanisms that lie behind tolerance induction • Engage with and immerse yourself within a learning journey across three conference days, tackling all elements of drug development from discovery to clinical development • Gain practical insight from those describing recent clinical trials and determine what mechanisms lie behind successful and unsuccessful clinical trials • Employ novel therapeutics in combination with antigen-specific immunotherapies and drive the progression of drug development towards the clinic • Take advantage of intimate networking opportunities with key opinion leaders from large pharma, biotech and academia through discursive and engaging platforms that spark conversation and debate WorkShop Day: Workshop A: Optimizing Novel Target Discovery Tuesday February 25: 9:00am-12:00pm Workshop B: Tolerance Induction in Antigen-Specific Immunotherapies: Applications to Transplantation Tuesday February 25: 1:00pm-4:00pm Time: 9:00 am - 6:00 pm Additional details will be posted as soon as information is available.
Feb 28, 2020 | CME 1.50 | Boston, Massachusetts
Amyloidosis Center Clinical Case Conference is organized by Boston University School of Medicine Continuing Medical Education Continuing Nursing Education (BUSM CME CNE) and will be held on Feb 28, 2020 at Boston University School of Medicine, Boston, Massachusetts, United States of America. Target Audience: The primary target audience for this activity is the amyloidosis center clinical team as well as respective fellows and residents. Accreditation: Boston University School of Medicine designates this live activity for a maximum of 1.5 AMA PRA Category Credit(s)™. Objectives: • Explain the complex symptoms of Amyloidosis • Facilitate multidisciplinary care for patients with amyloidosis disease • Screen amyloidosis patients for clinical trials • Discuss current amyloidosis research Additional details will be posted as soon as information is available.